Skip to main content
. 2020 Jan 24;10:1143. doi: 10.1038/s41598-020-57560-3

Figure 2.

Figure 2

PDD005 improves cognitive performance in aging mice. Aging WT mice were exposed by i.p. administration to PDD005 at 3 mg/kg/day or vehicle for 28 days. (A) Graph showing that PDD005 rescues cognitive deficit in aging mice 3–4 weeks after treatment. Cognitive abilities were assessed by means of the percentage of alternation in the T-maze test. One-way ANOVA with the Tukey’s multiple comparison test for post hoc analysis were performed and ***P < 0.001 indicates significant differences between PDD005 and aged vehicle group. Data expressed as means ± SEM with n = 10 mice/condition. (B,C) Plots showing the effect of PDD005 on relative mRNA expression levels of SYP (B) and PSD95 (C) in aging mice treated subchronically with PDD005. Transcriptional expression was quantified by RT-PCR and expressed as the relative expression of specific genes normalized to the housekeeping gene HPRT (2−ΔCt). One-way ANOVA and Tukey’s multiple comparison test for post hoc analysis were performed. *P < 0.05 and **P < 0.01 indicate significant differences between PDD005 and the aged vehicle group. Data expressed as means ± SEM with n = 4–6 mice/condition.